Home > Healthcare IT > Global Anthrax Treatment Market Share and Forecast to 2031 | Straits Research
Straits Research

Anthrax Treatment Market

Anthrax Treatment Market: Information by Route of Transmission (Cutaneous, Inhalation, Gastrointestinal Anthrax, and Injection Anthrax), Drug Class and Regional Outlook - Forecast Till 2031

Table of Content Download Sample

Market Snapshot

market snapshot
Base Year:
2022
Study Period:
2021-2031
CAGR:
7.5 %
Fastest Growing Market:
Asia Pacific
Largest Market:
North America

Global Anthrax Treatment market size was valued at USD 332.06 million in 2022. It is projected to reach USD 636.65 million by 2031, growing at a CAGR of 7.5% during the forecast period (2023-2031).

Anthrax Therapeutics are used to treat infections caused by Bacillus anthracis transmitted by livestock. Anthrax spores are transmitted through various routes including cutaneous, inhalation, injection, and gastrointestinal. The spores, when activated, release toxic substances that can cause swelling, internal bleeding, and tissue death. Today, the incidence of anthrax has reduced to a great extent in developed countries as a result of improved industrial hygiene and vaccination program. However, the rate incidence is high among underdeveloped and developing countries wherein routine vaccination programs against anthrax does not exist.

Get more information on this report Download Sample Report

Market Dynamics

Post-September 2001 bioterrorism attack in the U.S, the market witnessed drastic changes and intensified research activities in anthrax therapeutics.  Global anthrax treatment market is projected to witness considerable growth on account of growing funding to conduct research and development activities in anthrax therapeutics and various strategies by the government agencies for stockpiling. Anthim injection, Anthrasil, BioThrax, Ciprofloxacin, and Doxycycline are some of the leading FDA approved anthrax therapeutics.

Intended Audience

  • Anthrax Therapeutics Manufacturers
  • Raw Material Suppliers
  • Potential Investors
  • Research and Development Institutes
  • Traders, Distributors, and Suppliers of Anthrax Treatment
  • Government and Military Organizations

Segmental Insights

Global anthrax treatment market is segmented by route of transmission, drug class, and end-use.

By route of transmission, the market is segmented into cutaneous anthrax, inhalation anthrax, gastrointestinal anthrax, and injection anthrax. In most of the reported cases, the cutaneous route is the most common, accounting for more than 80% of the cases. As per the European Centre for Disease Prevention and Control, nine cases of cutaneous anthrax were reported from Hungary in 2014. Moreover, the transmission from the gastrointestinal route is also rising with increasing consumption of raw uncooked meat.

By treatment type, the anthrax treatment market is segmented into antibiotics, monoclonal antibodies, and others. New drug development and approvals are the key factors attributing to the overall market growth. For instance, in March 2016, the U.S. FDA approved obiltoxaximab injection, ‘Anthim,’ for treating inhalation anthrax and in November 2015, Emergent BioDefense Operations Lansing LLC received FDA approval for its Anthrax Vaccine Adsorbed, BioThrax. Issuance of emergency dispensing information, by the U.S. FDA is also boosting the market growth.

By end use, the anthrax treatment market is segmented into hospitals and clinics, ambulatory surgery centers, government agencies, and others. Government agencies accounted for the largest revenue share, nearly 86.7% of the product sales of Emergent Biosolutions, Inc. were to the government agencies. Altimune, Inc., another leading market player, has stated that all its revenue had been derived from grants and the U.S. government contracts. 

Regional Insights

Geographically, the global anthrax treatment market is segmented into four regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa (LAMEA).

Regional Growth Insights Request Sample Pages

North America dominated the global market in 2018 owing to high government funding, supportive strategies, and the presence of key players in this region. The supportive strategies include National Stockpile Strategy, vaccination campaign, and Anthrax Vaccine Immunization Program, conducted by the U.S. Department of Defense, wherein over 3.2 million people received more than 13.1 million doses of vaccines between 1998 to 2015.

Asia Pacific is another leading regions in terms of market growth as anthrax is one of the common endemics in China, and in recent years, several anthrax outbreaks have been reported in China. From 2018, nearly 106 cases of anthrax were reported in the country. The Chinese government is taking efforts and initiatives to mitigate the risk of anthrax.

Anthrax is a rear disease in Europe as only a few numbers of cases reported per year. In 2014, nearly 16 cases of anthrax were reported in EU/EEA countries. To mitigate the risk of anthrax-related bioterrorism, European Commission formed a preparedness and response program for attacks by biological and chemical agents (BICHAT) in 2002. In 2012, the U.S. agreed to fund USD 6.5 million to support the U.K’s Health Protection Agency for developing anthrax vaccine .

LAMEA is presently in the nascent phase of market growth. However, the presence of a large number of populations in contact with the livestock represents favorable market opportunities.

Key Players

Some of the key players in the global anthrax market are

  • Glaxo SmithKline Pharmaceuticals Ltd.
  • Elusys Therapeutics Inc.
  • Emergent BioSolutions Inc.
  • Altimune Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Bayer AG.

Report Scope

Report Metric Details
Market Size USD in 636.65 million By 2031
CAGR CAGR 7.5%
Historical Data 2020-2021
Base Year 2022
Forecast Period 2023-2031
Forecast Units Value (USD Million)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
Segments Covered by Route of Transmission (Cutaneous, Inhalation, Gastrointestinal Anthrax, and Injection Anthrax), Drug Class
Geographies Covered North America, Europe, Asia-Pacific, LAME and Rest of the World
Key Companies Profiled/Vendors Glaxo SmithKline Pharmaceuticals Ltd., Elusys Therapeutics, Inc., Emergent BioSolutions, Inc., Altimune, Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, and Bayer AG.,
Key Market Opportunities Rapid Growth In Healthcare It Industry Enhances Anthrax Treatment Market

Anthrax Treatment Market Segmentation

By Route of Transmission

  • Cutaneous Anthrax
  • Inhalation Anthrax
  • Gastrointestinal Anthrax
  • Injection Anthrax

By Drug Class

  • Antibiotics
  • Immunoglobulins
  • Others

By End Use

  • Hospitals and clinics
  • Ambulatory surgery centers
  • Government agencies
  • Others

Regions Covered

  • North America

    • U.S.
    • Canada
    • Mexico
  • Europe

    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific

    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA

    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Why Buy This Report?

  • Historical inferences, findings & analysis of the market from 2020 to 2021
  • Projections and performance forecast analysis for the future from 2023 to 2031
  • Production and consumption point of view (POV) analysis
  • Market drivers, restraint and opportunity analysis, to define market dynamics covering industry, regulatory, innovation, technological & pricing trends
  • Comprehensive competitive landscape mapping with recent development covering market leadership, competency, sustainability, and prospects
Price Starts From
USD4250

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report
Want to learn more about recent trends and data ?
They Already Trust Us :
Veto-Pharma
Nippon Becton Dickinson
Merck
Argon Medical Devices
Abbott
Johnson & Johnson
Need Assistance?
+1 646 480 7505 (U.S.)
+44 208 068 9665 (U.K.)
Looking For Custom Report ?

Report Benefits

  • Develop business strategies by understanding the trends shaping and driving the Market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the company share of market leaders.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track sales in the global and country-specific Market.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Check Our License Options :
Report Snapshot

As featured on :

clients
Trusted by Fortune 500
Over 30000+ subscribers